Cancer patients can develop various types of pulmonary hypertension (PH). Medications such as carfilzomib, dasatinib, and ponatinib can lead to type 1 PH. Anthracyclines and other agents may cause cancer therapy-related cardiac dysfunction (CTRCD), which can result in type 2 PH. Drugs like bleomycin and chest radiotherapy can induce pulmonary fibrosis, leading to type 3 PH. Due to the frequent occurrence of venous thromboembolism (VTE) in cancer patients, type 4 PH is the most common. Pulmonary tumor thrombotic microangiopathy can contribute to type 5 PH. The diagnosis and management of PH in cancer patients can refer to guidelines for aortic and peripheral vascular diseases. If PH is related to cancer therapy, discontinuation of the corresponding antitumor agents may be considered when necessary.